TRV-2026-1229Version 3 · Revised

Saved · see the current record

Why this version exists

Copy cleanup: removed remarks about truncated source text.

The exact text we saved

This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.

TRUVACE RECORD VERSION
record: TRV-2026-1229
version: 3
kind: revised
reason: Copy cleanup: removed remarks about truncated source text.
timestamp: 2026-11-04T09:00:01.002623Z
status: published
lens: general
sector: health
headline: Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI
dek: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational...
gain_title: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.
problem_title: (none)
trace_subject: (none)
gain_reading: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.
gain_evidence: design and optimize novel enzyme therapies for BioMarin's pipeline | Profluent announced a collaboration with BioMarin Pharmaceutical Inc.
problem_reading: (none)
problem_evidence: (none)
quick_read: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement.
limitation: 
tag: Context
key_points: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. | The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline. | Under the agreement Profluent will apply its foundational AI technology to the effort.
rundown: On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies.

The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline.
sources:
- journalism | MarketScreener | https://www.marketscreener.com/news/profluent-and-biomarin-pharmaceutical-inc-partner-to-design-novel-medicines-using-ai-ce785ad3d88bf623 | 2026-09-30
prev: bc4a4ead1d7a34684900415e70709ed08b552759b3815873f44e9be914b8bf75
SHA-256 hash
46339b270885b83b0331b02b4db3002cca5344da98d74bc367bd8fc01275df44
Previous version’s hash
bc4a4ead1d7a34684900415e70709ed08b552759b3815873f44e9be914b8bf75
Check this record hasn’t been altered
How to check it yourself, without trusting this page

Download any version from /api/record/TRV-2026-1229 and hash its canonical field yourself, for example with shasum -a 256. You should get its content_hash. Each version’s text also ends with prev:and the hash of the version before it (version 1 points to 64 zeros). If anyone had changed a single character of any version after it was saved, those hashes wouldn’t line up.